注：本产品仅用于科研，不可用于临床
Verteporfin试剂简介
Verteporfin (CL 318952) 是一种用于光动力疗法的光敏剂，用于消除与年龄相关的黄斑变性等疾病相关的眼内异常血管。 Verteporfin 是一种 YAP 抑制剂，可破坏 YAP-TEAD 相互作用。Verteporfin 可以诱导细胞凋亡 (apoptosis)。Verteporfin 是一种自噬 (autophagy) 抑制剂，通过抑制自噬小体形成，在早期阻断自噬。
Verteporfin试剂简介生物活性
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation
| IC50 & Target | IC50: YAP-TEAD interaction | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究 (In Vitro) | Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 (In Vivo) | Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 分子量 | 718.79 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C82H84N8O16 | ||||||||||||||||
| CAS 号 | 129497-78-5 | ||||||||||||||||
| 中文名称 | 维替泊芬 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL (139.12 mM; Need ultrasonic) DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
|
采购中心
